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Abstract
Derivatisation of parent structure in terpenoids often results in enhancement of biological activity of newly obtained
compounds. Thymol, a naturally occurring phenol biosynthesized through the terpene pathway, is a well known biocide
with strong antimicrobial attributes and diverse therapeutic activities. We have aimed our study on a single modification
of phenolic functionality in thymol in order to obtain a small focused library of twenty thymyl esters, ten of which we-
re new compounds. All compounds were involved in in vitro antimicrobial testing. Another important aspect of current
study was implementation of in silico calculation of physico-chemical, pharmacokinetic and toxicological properties,
which could be helpful by giving an additional guidance in further research.
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1. Introduction
Terpenoids constitute an abundant and potent group
of natural products, which play an important role in the
enzyme systems of plants and reflect conspicuous biologi-
cal activity against various pests. Their biological activity
is believed to be related to the nature and the position of
functional groups or substituents.1 Chemical modification
of natural monoterpenoids has been reported to result in
enhancement of biological activities when compared to
parent compounds.2–5 Thymol (1), a monoterpene
biosynthetically directly related to para-cymene (1a)6 and
a naturally occurring phenol, is a well known biocide and
most dominant constituent of the oils of thyme (Thymus
vulgaris L.) and oregano (Origanum vulgare L.).
Numerous studies have demonstrated the antimicro-
bial effect of thymol, ranging from inducing antibiotic
susceptibility in drug-resistant pathogens through a syner-
gistic effect, to a powerful antioxidant properties.7
Thymol has been shown to be an effective fungicide, par-
ticularly against fluconazole-resistant strains8 and was de-
monstrated to have strong antimutagenic effect.9 In addi-
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Sheme 1. Chemical structures of thymol (1) and para-cymene (1a).
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tion, there is evidence that thymol has antitumor proper-
ties.10
The primary mode of antibacterial action of thymol
is not fully known, but is believed to involve outer- and in-
ner membrane disruption, and interaction with membrane
proteins and intracellular targets.11–16 The mode of action
of thymol against yeast and fungi has been sparsely inve-
stigated, though certain studies point to interactions with
the cell envelope and intracellular targets.16–19
Thymyl derivatives are well represented in Astera-
ceae plants, particularly within tribes Senecioneae, Eupa-
torieae, Inuleae and Helenieae. In some Inula, Doronicum
and Pulicaria species, thymyl derivatives rather than ses-
quiterpenoids are the major root constituents.20–23 A re-
view by Talavera-Aleman and collaborators24 estimated
that only 10% of known functionalized thymyl derivatives
have been employed in biological testing, showing vast
array of diverse activities, such as antimicrobial4,5,22,25–27
(several papers reporting inhibitory activity against
plants’ pathogenic fungi22,26), antioxidant,28 antinocicepti-
ve,29 anti-parasitic (antileishmanial),30,31 antiprotozoal,32
insecticidal33 and piscicidal34 activity. The usefulness of
thymyl derivatives as transdermal drug delivery enhancers
has also been reported.35
There are several papers reporting isolation, syn-
thesys4,23,29,33,36 and biological activity4,5,22,25,28–30,33 of
thymyl esters. Grodnitzky and Coats33 have tested insecti-
cidal activity of thymyl esters of acetic, dichloracetic,
trichloroacetic, chlorodifluoroacetic, pivalic and chloropi-
valic acid on Musca domestica. Mathela and collabora-
tors4 evaluated antibacterial activity of thymyl esters of
acetic, propanoic, 2-methylpropanoic, 3-methylbutanoic,
but-2-enoic, benzoic and 2-phenylacetic acids and repor-
ted the enhancement in the activity of derivatives in com-
parison to thymol. Kumbhar and Dewang5 tested antifun-
gal activity and observed structure-activity relationship,
stating that thymyl ethers showed better antifungal po-
tency over esters (thymyl acetate, benzoate, cinnamate,
dithymyl malonate, succinate and glutarate) and that the
addition of a methylene group or a carbon, an olefinic
bond or an aromatic moiety in side chain led to com-
pounds with improved potency over the parent compound
(thymol).5 Angeles-Lopez et al.29 have undertaken a study
to establish the potential acute toxicity and the antinoci-
ceptive activity in animal models of thymyl esters of
C2–C6 straight chain, C4–C6 acids positional isomers, dia-
steroisomers of 2-pentenoic, and of benzoic acid, repor-
ting several esters with antinociceptive effect at a dose of
1 mg/kg.
Keeping in view diverse pharmacological activities
of thymol7–19 and preliminary results on bioactivity of
thymyl derivatives4,5,22,25,28–30,33 we have set the aim of our
study. By making a single modification of a phenolic
functionality in thymol we have obtained a series of ester
compounds (3a–t), performed their structural characteri-
zation, in vitro antimicrobial testing and in silico calcula-
tion of physico-chemical, pharmacokinetic and toxicolo-
gical properties. The most important contribution of this
study is the synthesis of ten new compounds (3i, 3k–s)
followed by results obtained in antimicrobial assay and in
silico calculations, which all together could be an impor-
tant aspect and an additional guidance in further research.
2. Materials and Methods
2. 1. Chemicals Used
All of the reagents, standards and solvents used we-
re of analytical reagent grade. Unless specified otherwise,
all chemicals were purchased from Merck (Darmstadt,
Germany).
2. 2. General Synthetic Procedures
Acetyl, benzoyl and palmitoyl chloride were purc-
hased from Sigma–Aldrich. The conversion of the other
carboxylic acids to acyl chlorides37,38 and the preparation
of thymyl esters utilized methods from the literature.39,40
Scheme 1 presents the synthesis of thymyl esters.
2. 2. 1. General Procedures for Synthesis of Acid
Chlorides
(a) An old procedure developed by Brown37 was
used for the preparation of volatile acid chlorides. This
procedure involves the action of a relatively slightly vola-
tile benzoyl chloride upon an organic acid. Following this
protocol, the synthesis of chlorides up to 10 carbons, as
well as 2-chloroacetyl chloride was achieved. In a round-
bottom flask equipped by a fractionating column 0.25 mol
of the acid and 0.375 mol of benzoyl chloride were placed
The mixture was heated until the boiling point was reac-
hed, and then the acid chloride was distilled from the reac-
tion mixture. The material so obtained was used directly
in the synthesis.
(b) For the preparation of chlorides higher than 10 C
atoms the corresponding acid was refluxed for 2 h with
thionyl chloride in CCl4.
38 The solvent and the excess of
thionyl chloride were removed with the aid of the water
pump vacuum.
The products obtained in either way were used di-
rectly in the synthesis.
2. 2. 2. General Procedure for the Synthesis of
Thymyl Esters 3a–t
Series of thymyl esters were made following the
procedure described by Paolini et al.39 A solution of acid
chloride (4.5 mmol) in CH2Cl2 (15 mL) was added drop
by drop to a cooled mixture (0 °C) of thymol (3.3 mmol)
and Et3N (4.5 mmol) in CH2Cl2 (20 mL). The mixture was
stirred at room temperature and then refluxed for 3 h. The
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organic layer was washed with water (3 × 200 mL), dried
over anhydrous Na2SO4 and concentrated under vacuum.
The esters were purified by column chromatography, sta-
tionary phase Silica Gel 60 (70–230 mesh), mobile phase
(hexane/diethyl ether, gradient 9:1 to 8:2). For yields, see
supplementary data.
Thymyl Acetate (3a)
Chromatographic purification gave colorless oil.
C12H16O2 (M = 192.25); yield 85%; MS (EI): m/z (%) 192
(M+) (11.3), 151 (4.8), 150 (42.6), 151 (4.8), 135 (100),
136 (11.0), 115 (7.3), 105 (4.7), 77 (5.1), 43 (4.1); RI
(HP5-MS): 1367; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.22 (1H, d, J = 8 Hz, Ar-H), 7.05 (1H, d, J = 8 Hz,
Ar-H), 6.84 (1H, s, Ar-H), 3.00 (1H, spt, J = 7 Hz, CH),
2.34 (6H, s, CH3), 1.22 (6H, d, J = 7 Hz, CH3); 
13C NMR
(125.76 MHz, CDCl3): δ (ppm) 169.77 (C=O), 147.84
(CAr), 136.95 (CAr), 136.52 (CAr), 127.52 (CAr), 126.78
(CAr), 123.23 (CAr), 26.89 (CH), 26.57 (CO-CH3), 22.99
(2 × CH3), 21.21 (CH3).
Thymyl 2-Chloroacetate (3b)
Chromatographic purification gave colorless oil.
C12H15O2Cl (M = 226.70); yield 85%; MS (EI): m/z (%)
226 (M+) (10.1), 150 (30.4), 149 (19.4), 136 (9.4), 133
(11.1), 115 (6.5), 105 (8.1), 91 (14.6), 77 (11.4); RI (HP5-
MS): 1572; 1H NMR (500.13 MHz, CDCl3): δ (ppm) 7.24
(1H, d, J = 8 Hz, Ar-H), 7.08 (1H, d, J = 7.6 Hz, Ar-H),
6.87 (1H, s, Ar-H), 4.33 (2H, s, CH2), 3.00 (1H, spt, J =
6.90 Hz, CH), 2.34 (3H, s, CH3), 1.22 (6H, d, J = 6.90 Hz,
CH3). 
13C NMR (125.76 MHz, CDCl3): δ (ppm) 166.11
(C=O), 147.45 (CAr), 136.81 (CAr), 136.79 (CAr), 127.64
(CAr), 126.60 (CAr), 122.20 (CAr), 40.74 (CH2), 27.01
(CH), 22.98 (2 × CH3), 20.77 (CH3-Ar).
Thymyl Propanoate (3c)
Chromatographic purification gave colorless oil.
C13H18O2 (M = 206.28); yield 82%; MS (EI): m/z (%) 206
(M+) (9.5), 151 (4.5), 150 (42.1), 135 (100), 136 (9.5),
115 (5.7), 105 (5.4), 91 (11.0), 77 (5.1), 57 (12.6); RI
(HP5-MS): 1455; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.04 (1H, d, J = 8 Hz,
Ar-H), 6.83 (1H, s, Ar-H), 2.99 (1H, spt, J = 14 Hz, CH),
2.63 (2H, q, J = 8 Hz, CH2), 2.33 (3H, s, CH3), 1.32 (3H,
m, CH3), 1.21 (6H, d, J = 7 Hz, CH3); 
13C NMR (125.76
MHz, CDCl3): δ (ppm) 173.16 (C=O), 147.93 (CAr),
136.96 (CAr), 136.5 (CAr), 126.69 (CAr), 123.24 (CAr),
122.77 (CAr), 27.73 (CH), 26.91 (CH2), 22.90 (CH3),
23.03 (2 × CH3), 9.31 (CH3).
Thymyl Butanoate (3d)
Chromatographic purification gave yellowish oil.
C14H20O2 (M = 220.31); yield 84%; MS (EI): m/z (%) 220
(M+) (9.7), 151 (6.1), 150 (55.5), 136 (9.5), 135 (100),
115 (5.4), 105 (5.7), 91 (10.4), 71 (9.3), 43 (7.1); RI
(HP5-MS): 1544; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.04 (1H, d, J = 8 Hz,
Ar-H), 6.82 (1H, s, Ar-H), 2.99 (1H, spt, J = 7 Hz, CH),
2.58 (2H, t, J = 7 Hz, CH2), 2.33 (3H, s, CH3), 1.84 (2H,
sxt, J = 7 Hz, CH2), 2.1 (6H, d, J = 7 Hz, CH3), 1.08 (3H,
t, J = 7 Hz, CH3); 
13C NMR (125.76 MHz, CDCl3): δ
(ppm) 172.34 (C=O), 147.88 (CAr), 136.98 (CAr), 136.49
(CAr), 126.66 (CAr), 125.99 (CAr), 123.24 (CAr), 36.24
(CH2), 26.90 (CH), 23.07 (2 × CH3), 18.55 (CH2), 13.78
(CH3).
Thymyl 2-Methylpropanoate (3e)
Chromatographic purification gave colorless oil,
C14H20O2 (M = 220.31); yield 75%; MS (EI): m/z (%) 220
(M+) (11.4), 150 (59.6), 136 (9.4), 135 (100), 115 (7.3),
105 (8.0), 91 (15.1), 77 (6.8), 71 (18.8), 43 (21.9); RI
(HP5-MS): 1495; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.03 (1H, d, J = 7.6
Hz, Ar-H), 6.81 (1H, s, Ar-H), 2.99 (1H, spt, J = 6.9 Hz,
CH), 2.85 (1H, spt, J = 7 Hz, CH), 2.33 (3H, s, CH3) 1.36
(6H, d, J = 7.3 Hz, 2 × CH3), 1.21 (6H, d, J = 6.9 Hz, 2 ×
CH3). 
13C NMR (125.76 MHz, CDCl3): δ (ppm) 175.71
(C=O), 147.99 (CAr), 136.97 (CAr), 136.47 (CAr), 126.62
(CAr), 126.56 (CAr), 122.14 (CAr), 33.95 (CH), 26.78
(CH), 22.99 (2 × CH3), 19.20 (CH3), 19.05 (2 × CH3).
Thymyl Pentanoate (3f)
Chromatographic purification gave colorless oil.
C15H22O2 (M = 234.33); yield 87%; MS (EI): m/z (%) 234
(M+) (8.1), 151 (7.4), 150 (67.6), 135 (100), 136 (9.3),
115 (5.5), 105 (6.1), 91 (10.7), 85 (8.0), 57 (16.4); RI
(HP5-MS): 1640; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.04 (1H, d, J = 8 Hz,
Ar-H), 6.82 (1H, s, Ar-H), 2.99 (1H, spt, J = 14 Hz, CH),
2.6 (2H, t, J = 7.6 Hz, CH2), 2.33 (3H, s, CH3), 1.79 (2H,
quin, J = 7.5 Hz, CH2), 1.49 (2H, sxt, J = 15 Hz, CH2),
1.21 (6H, d, J = 6.9 Hz, 2 × CH3), 1.01 (3H, t, J = 7.5 Hz,
CH3); 
13C NMR (125.76 MHz, CDCl3): δ (ppm) 172.45
(C=O), 147.90 (CAr), 136.95 (CAr), 136.45 (CAr), 126.96
(CAr), 126.3 (CAr), 122.7 (CAr), 34.06 (CH2), 27.06 (CH2),
27.02 (CH), 22.28 (CH2), 22.96 (2 × CH3), 20.76 (CH3-
Ar), 18.55 (CH2), 13.8 (CH3).
Thymyl 3-Methylbutanoate (3g)
Chromatographic purification gave colorless oil.
C15H22O2 (M = 234.33); yield 81%; MS (EI): m/z (%) 234
(M+) (8.9), 151 (8.3), 150 (71.4), 135 (100), 136 (9.3),
115 (5.4), 105 (6.8), 91 (11.0), 85 (9.3), 52 (21.5); RI
(HP5-MS): 1590; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.04 (1H, d, J = 7.6
Hz, Ar-H), 6.81 (1H, s, Ar-H), 3.00 (1H, spt, J = 6.9 Hz,
CH), 2.48 (2H, d, J = 6.9 Hz, CH2), 2.33 (3H, s, CH3),
2.28 (1H, m, CH), 1.49 (2H, sxt, J = 15 Hz, CH2), 1.20
(6H, d, J = 6.9 Hz, 2 × CH3), 1.09 (6H, d, J = 6.6 Hz, 2 ×
CH3); 
13C NMR (125.76 MHz, CDCl3): δ (ppm) 171.74
(C=O), 147.87 (CAr), 136.99 (CAr), 136.45 (CAr), 126.99
(CAr), 126.32 (CAr), 122.70 (CAr), 43.34 (CH2), 26.98
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(CH2), 25.98 (CH), 23.01 (2 × CH3), 22.44 (2 × CH3),
20,78 (CH3-Ar).
Thymyl Hexanoate (3h)
Chromatographic purification gave colorless oil,
C16H24O2 (M = 248.36); yield 79%; MS (EI): m/z (%) 248
(M+) (7.3), 151 (8.9), 150 (79.2), 136 (9.4), 135 (100), 105
(6.7), 99 (6.6), 91 (10.5), 71 (9.7), 43 (9.3); RI (HP5-MS):
1738; 1H NMR (500.13 MHz, CDCl3): δ (ppm) 7.20
(1H,d, J = 8 Hz, Ar-H), 7.03 (1H, d, J = 7.6 Hz, Ar-H),
6.81 (1H, s, Ar-H), 2.98 (1H, spt, J = 6.9 Hz, CH), 2.58
(2H, t, J = 7.6 Hz, CH2), 2.32 (3H, s, CH3), 1.79 (2H, quin,
J = 7.5 Hz, CH2), 1.41 (4H, m, CH2), 1.20 (6H, d, J = 6.9
Hz, CH3), 0.95 (3H, m, CH3); 
13C NMR (125.76 MHz,
CDCl3): δ (ppm) 172.50 (C=O), 147.90 (CAr), 137.00
(CAr), 136.50 (CAr), 127.00 (CAr), 126.3 (CAr), 122.7 (CAr),
34.38 (CH2), 31.36 (CH2), 27.08 (CH), 24.76 (CH2), 23.03
(2 × CH3), 22.36 (CH2), 20.83 (CH3), 13.94 (CH3).
Thymyl Heptanoate (3i)
Chromatographic purification gave colorless oil.
C17H26O2 (M = 262.39); yield 84%; MS (EI): m/z (%) 262
(M+) (7.6), 151 (10.8), 150 (95.6), 149 (5.3), 136 (9.4),
135 (100), 113 (5.6), 105 (6.4), 91 (9.8), 43 (9.4); RI
(HP5-MS): 1840; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.03 (1H, d, J = 8 Hz,
Ar-H), 6.81 (1H, s, Ar-H), 2.99 (1H, spt, J = 14 Hz, CH),
2.59 (2H, t, J = 8 Hz, CH2), 2.33 (3H, s, CH3), 1.79 (2H,
m, CH2), 1.45 (2H, m, CH2), 1.36 (4H, m, CH2), 1.22 (6H,
m, CH3), 0.92 (3H, m, CH3); 
13C NMR (125.76 MHz,
CDCl3): δ (ppm) 172.53 (C=O), 147.91 (CAr), 136.99
(CAr), 136.49 (CAr), 126.99 (CAr), 126.33 (CAr), 122.73
(CAr), 34.39 (CH2), 31.44 (CH2), 28.84 (CH2), 27.03
(CH), 25.0 (CH2), 23.0 (2 × CH3), 22.49 (CH2), 20.8
(CH3-Ar), 14.01 (CH3).
Thymyl Octanoate (3j)
Chromatographic purification gave colorless oil.
C18H28O2 (M = 276.41); yield 85%; MS (EI): m/z (%) 276
(M+) 151 (11.3), 150 (100), 136 (9.3), 135 (98.3), 109
(6.4), 105 (7.2), 91 (10.9), 57 (27.2), 55 (9.4), 43 (6.3); RI
(HP5-MS): 1938; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 7.9 Hz, Ar-H), 7.03 (1H, d, J = 7.9
Hz, Ar-H), 6.81 (1H, s, Ar-H), 2.99 (1H, spt, J = 6.9 Hz,
CH), 2.59 (2H, t, J = 7.5 Hz, CH2), 2.33 (3H, s, CH3), 1.79
(2H, quin, J = 7.5 Hz, CH2), 1.47–1.29 (8H, m, CH2), 1.21
(6H, bd, CH3), 0.92 (3H, t, J = 6.8 Hz, CH3); 
13C NMR
(125.76 MHz, CDCl3): δ (ppm) 174.20 (C=O), 148.00
(CAr), 136.80 (CAr), 136.09 (CAr), 127.00 (CAr), 126.30
(CAr), 122.80 (CAr), 36.10 (CH2), 34.00 (CH2), 32.04
(CH2), 29.00 (CH2), 28.00 (CH), 26.00 (CH2), 23.0 (2 ×
CH3), 22.10 (CH2), 20.5 (CH3-Ar), 14.00 (CH3).
Thymyl Nonanoate (3k)
Chromatographic purification gave colorless oil.
C19H30O2 (M = 290.44); yield 79.80%; MS (EI): m/z (%)
290 (M+) (5.7), 151 (12.0), 150 (100), 141 (3.2), 136
(7.7), 135 (79.0), 121 (3.4), 117 (2.0), 115 (2.3), 91 (3.3);
RI (HP5-MS): 2044; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.24–7.19 (1H, m, Ar-H), 7.06–7.01 (1H, bd, Ar-
H), 6.84–6.79 (1H, bs, Ar-H), 3.04–2.93 (1H, bm, CH),
2.63–2.56 (2H, bm, CH2), 2.36–2.31 (3H, s, CH3),
1.84–1.75 (2H, bm, CH2), 1.49–1.26 (10H, bm, CH2),
1.24–1.18 (6H, bt, CH3), 0.95–0.87 (3H, bm, CH3); 
13C
NMR (125.76 MHz, CDCl3): δ (ppm) 172.53 (C=O),
147.91 (CAr), 136.99 (CAr), 136.49 (CAr), 126.99 (CAr),
126.33 (CAr), 122.73 (CAr), 36.10 (CH2), 34.20 (CH2),
32.00 (CH2), 28.80 (2 × CH2), 27.60 (CH), 25.60 (CH2),
23.0 (2 × CH3), 22.50 (CH2), 20.8 (CH3-Ar), 14.01 (CH3).
Thymyl Decanoate (3l)
Chromatographic purification gave colorless oil.
C20H32O2 (M = 304.47); yield 75.50%; MS (EI): m/z (%):
304 (M+) (4.6), 151 (12.3), 150 (100), 136 (6.7), 135
(71.9), 109 (5.3), 91 (5.7), 71 (4.8), 57 (4.8), 55 (5.5); RI
(HP5-MS): 2147; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.03 (1H, d, J = 7.6
Hz, Ar-H), 6.82 (1H, s, Ar-H), 2.99 (1H, spt, J = 6.9 Hz,
CH), 2.59 (2H, t, J = 7.5 Hz, CH2), 2.33 (3H, s, CH3), 1.8
(2H, quin, J = 7.5 Hz, CH2), 1.49–1.25 (12H, bm, CH2),
1.21 (6H, d, J = 6.9 Hz, CH3), 0.91 (3H, t, J = 6.2 Hz,
CH3); 
13C NMR (125.76 MHz, CDCl3): δ (ppm) 172.52
(C=O), 147.91 (CAr), 136.99 (CAr), 136.48 (CAr), 126.99
(CAr), 126.33 (CAr), 122.73 (CAr), 34.39 (CH2), 31.85
(CH2), 29.43 (CH2), 29.25 (2 × CH2), 29.17 (CH2), 27.04
(CH), 25.05 (CH2), 23.0 (2 × CH3), 22.67 (CH2), 20.8
(CH3-Ar), 14.09 (CH3).
Thymyl Undecanoate (3m)
Chromatographic purification gave colorless oil.
C21H34O2 (M = 318.49); yield 82.00%; MS (EI): m/z (%)
318 (M+) 151 (7.9), 150 (100), 149 (7.4), 135 (80.1), 134
(6.8), 105 (7.0), 91 (13.3), 57 (18.4), 55 (20.2), 43 (12.1);
RI (HP5-MS): 2245; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.03 (1H, d, J = 7.6
Hz, Ar-H), 6.82 (1H, s, Ar-H), 2.99 (1H, spt, J = 13.9 Hz,
CH), 2.59 (2 H, t, J = 7.46 Hz, CH2), 2.33 (3H, s, CH3),
1.79 (2H, quin, J = 7.54 Hz, CH2), 1.41–1.48 (2H, m,
CH2), 1.26–1.39 (12H, m, CH2), 1.21 (6H, d, J = 6.94 Hz,
CH3), 0.91 (3H, t, J = 6.76 Hz, CH3); 
13C NMR (125.76
MHz, CDCl3): δ (ppm) 172.52 (C=O), 147.91 (CAr),
136.99 (CAr), 136.48 (CAr), 126.99 (CAr), 126.33 (CAr),
122.73 (CAr), 34.39 (CH2), 31.88 (CH2), 29.54 (CH2),
29.47 (CH2), 29.30 (CH2), 29.26 (CH2), 29.17 (CH2),
27.04 (CH), 25.05 (CH2), 23.0 (2 × CH3), 22.67 (CH2),
20.8 (CH3-Ar), 14.10 (CH3).
Thymyl Dodecanoate (3n)
Chromatographic purification gave colorless oil.
C22H36O2 (M = 332.52); yield 76.30%; MS (EI): m/z (%)
332 (M+) (4.4), 151 (15.2), 150 (100), 136 (6.7), 135
(67.8), 109 (7.3), 91 (4.6), 57 (6.4), 55 (5.6), 43 (3.6); RI
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(HP5-MS): 2355; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.03 (1H, d, J = 8 Hz,
Ar-H), 6.81 (1H, s, Ar-H), 2.98 (1H, spt, J = 6.9 Hz, CH),
2.59 (2 H, t, J = 7.6 Hz, CH2), 2.33 (3H, s, CH3), 1.79 (2H,
quin, J = 7.5 Hz, CH2), 1.48–1.40 (14H, m, CH2), 1.20
(6H, d, J = 6.9 Hz, CH3), 0.90 (3H, t, J = 6.8 Hz, CH3);
13C NMR (125.76 MHz, CDCl3): δ (ppm) 172.55 (C=O),
147.91 (CAr), 136.99 (CAr), 136.49 (CAr), 126.99 (CAr),
126.33 (CAr), 122.73 (CAr), 34.40 (CH2), 31.90 (CH2),
29.60 (2 × CH2), 29.47 (CH2), 29.33 (CH2), 29.18 (CH2),
29.17 (CH2), 27.04 (CH), 25.06 (CH2), 23.01 (2 × CH3),
22.68 (CH2), 20.81 (CH3-Ar), 14.10 (CH3).
Thymyl Tridecanoate (3o)
Chromatographic purification gave colorless oil,
C23H38O2 (M = 346.55); yield 85.1%; MS (EI): m/z (%)
346 (M+) (2.4), 347 (0.6), 197 (0.9), 152 (0.9), 151 (12.9),
150 (100), 137 (0.4), 136 (5.0), 135 (54.2), 119 (0.5); RI
(HP5-MS): 2453; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 7.98 Hz, Ar-H), 7.03 (1H, d, J =
7.98 Hz, Ar-H), 6.81 (1H, s, Ar-H), 2.98 (1H, spt, J = 13.9
Hz, CH), 2.59 (2 H, t, J = 7.63 Hz, CH2), 2.33 (3H, s,
CH3), 1.79 (2H, quin, J = 7.54 Hz, CH2), 1.26–1.48 (16H,
m, CH2), 1.20 (6H, d, J = 6.94 Hz, CH3), 0.90 (3H, t, J =
6.76 Hz, CH3); 
13C NMR (125.76 MHz, CDCl3): δ (ppm)
172.5 (C=O), 147.9 (CAr), 137 (CAr), 136.5 (CAr), 127.0
(CAr), 126.3 (CAr), 122.7 (CAr), 34.43 (CH2), 31.94 (CH2),
29.67 (2 × CH2), 29.51 (CH2), 29.38 (CH2), 29.3 (CH2),
29.22 (CH2), 27.08 (CH), 25.09 (CH2), 23.04 (2 × CH3),
22.71 (CH2), 20.83 (CH3-Ar), 14.13 (CH3).
Thymyl Tetradecanoate (3p)
Chromatographic purification gave colorless oil.
C24H40O2 (M = 360.57); yield 72.05%; MS (EI): m/z (%)
360 (M+) (1.9), 152 (0.9), 151 (12.7), 150 (100), 135
(50.7), 134 (4.8), 121 (1.3), 117 (0.7), 115 (1.9), 109
(5.1); RI (HP5-MS): 2555; 1H NMR (500.13 MHz, CDC-
l3): δ (ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.03 (1H, d, J =
7.6 Hz, Ar-H), 6.81 (1H, s, Ar-H), 2.99 (1H, spt, J = 6.9
Hz, CH), 2.59 (2H, t, J = 7.6 Hz, CH2), 2.33 (3H, s, CH3),
1.79 (2H, quin, J = 7.5 Hz, CH2), 1.49–1.25 (20H, m,
CH2), 1.21 (6H, d, J = 6.9 Hz, CH3), 0.91 (3H, t, J = 6.9
Hz, CH3); 
13C NMR (125.76 MHz, CDCl3): δ (ppm)
172.53 (C=O), 147.93 (CAr), 136.99 (CAr), 136.48 (CAr),
126.99 (CAr), 126.33 (CAr), 122.73 (CAr), 34.39 (CH2),
31.92 (CH2), 29.67 (CH2), 29.65 (2 × CH2), 29.60 (CH2),
29.48 (CH2), 29.35 (CH2), 29.27 (CH2), 29.19 (CH2),
27.04 (CH), 25.06 (CH2), 23.00 (2 × CH3), 22.68 (CH2),
20.80 (CH3-Ar), 14.10 (CH3).
Thymyl Pentadecanoate (3q)
Chromatographic purification gave colorless oil.
C25H42O2 (M = 374.60); yield 68.90%; MS (EI): m/z (%)
374 (M+) (5.3), 151 (23.9), 150 (100), 149 (7.5), 136
(8.3), 135 (76.4), 109 (11.9), 71 (4.4), 57 (7.0), 55 (6.2);
RI (HP5-MS): 2669; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 8 Hz, Ar-H), 7.03 (1H, d, J = 8 Hz,
Ar-H), 6.81 (1H, s, Ar-H), 2.99 (1H, spt, J = 6.90 Hz,
CH), 2.59 (2H, t, J = 7.6, CH2), 2.33 (3H, s, CH3), 1.79
(2H, quin, J = 7.5 Hz, CH2), 1.48–1.24 (22H, bm, CH2),
1.21 (6H, d, J = 6.90 Hz, CH3), 0.9 (3H, t, J = 6.90 Hz,
CH3); 
13C NMR (125.76 MHz, CDCl3): δ (ppm) 172.54
(C=O), 147.92 (CAr), 136.99 (CAr), 136.49 (CAr), 126.99
(CAr), 126.33 (CAr), 122.73 (CAr), 34.40 (CH2), 31.92
(CH2), 29.67 (2 × CH2), 29.65 (2 × CH2), 29.60 (CH2),
29.48 (CH2), 29.35 (CH2), 29.27 (CH2), 29.18 (CH2),
27.04 (CH), 25.06 (CH2), 23.01 (2 × CH3), 22.68 (CH2),
20.81 (CH3-Ar), 14.10 (CH3).
Thymyl Hexadecanoate (3r)
Chromatographic purification gave colorless oil.
C26H44O2 (M = 388.63); yield 95.06%; MS (EI): m/z (%)
388 (M+) (5.8), 150 (100), 135 (65.4), 121 (4.3), 108
(3.4), 105 (4.0), 97 (3.3), 69 (5.6), 55 (6.1), 43 (4.3); RI
(HP5-MS): 2772; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.20 (1H, d, J = 8 Hz, Ar-H), 7.03 (1H, d, J = 8 Hz,
Ar-H), 6.81 (1H, s, Ar-H), 2.98 (1H, spt, J = 6.90 Hz,
CH), 2.58 (2H, t, J = 7.5, CH2), 2.33 (3H, s, CH3), 1.78
(2H, quin, J = 7.5 Hz, CH2), 1.51–1.28 (24H, bm, CH2),
1.21 (6H, d, J = 6.90 Hz, CH3), 0.9 (3H, t, J = 6.90 Hz,
CH3); 
13C NMR (125.76 MHz, CDCl3): δ (ppm) 172.50
(C=O), 147.94 (CAr), 136.99 (CAr), 136.49 (CAr), 126.99
(CAr), 126.33 (CHAr), 122.73 (CAr), 34.40 (CH2), 31.92
(CH2), 29.68 (2 × CH2), 29.65 (2 × CH2), 29.60 (CH2),
29.47 (CH2), 29.35 (CH2), 29.27 (CH2), 29.19 (CH2),
25.06 (CH2), 23.01 (2 × CH3), 22.68 (CH2), 20.81 (CH3-
Ar), 14.10 (CH3).
Thymyl Heptadecanoate (3s)
Chromatographic purification gave colorless oil.
C27H46O2 (M = 402.65); yield 72.50%; MS (EI): m/z (%)
402 (M+), 151 (19.6), 150 (100), 136 (5.4), 135 (55.2),
109 (9.2), 71 (3.3), 69 (3.0), 57 (5.5), 55 (5.0), 43 (3.0); RI
(HP5-MS): 2870; 1H NMR (500.13 MHz, CDCl3): δ
(ppm) 7.21 (1H, d, J = 7.9 Hz, Ar-H), 7.03 (1H, d, J = 7.9
Hz, Ar-H), 6.82 (1H, s, Ar-H), 2.99 (1H, spt, J = 6.80 Hz,
CH), 2.59 (2H, t, J = 7.5, CH2), 2.33 (3H, s, CH3), 1.8
(2H, quin, J = 7.5 Hz, CH2), 1.48–1.25 (26H, bm, CH2),
1.21 (6H, d, J = 6.80 Hz, CH3), 0.91 (3H, t, J = 6.90 Hz,
CH3); 
13C NMR (125.76 MHz, CDCl3): δ (ppm) 172.50
(C=O), 147.9 (CAr), 137.0 (CAr), 136.5 (CAr), 127.0 (CAr),
126.30 (CHAr), 122.70 (CAr), 34.43 (CH2), 31.96 (CH2),
29.72 (2 × CH2), 29.52 (2 × CH2), 29.40 (CH2), 29.31
(CH2), 29.22 (CH2), 26.54 (CH2), 25.09 (CH2), 23.05 (2 ×
CH3), 22.72 (CH2), 20.84 (CH3-Ar), 14.15 (CH3).
Thymyl Benzoate (3t)
Chromatographic purification gave white solid.
C17H18O2 (M = 254.32); yield 95%; MS (EI): m/z (%): 254
(M+), (9.7), 150 (2.7), 149 (25.0), 133 (2.3), 106 (9.4),
105 (100), 91 (5.1), 78 (3.1), 77 (34.5), 51 (4.1); RI (HP5-
MS): 1955; 1H NMR (500.13 MHz, CDCl3): δ (ppm) 8.26
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(2H, d, J = 7.3 Hz, Ar-H), 7.68 (1H, t, Ar-H), 7.56 (2H, t,
Ar-H), 7.28 (1H, d, J = 8 Hz, Ar-H), 7.11 (1H, d, J = 8 Hz,
Ar-H), 6.98 (1H, s, Ar-H), 3.10 (1H, spt, J = 6.90 Hz,
CH), 2.38 (3H, s, CH3), 1.25 (6H, d, J = 6.90 Hz, CH3);
13C NMR (125.76 MHz, CDCl3): δ (ppm) 165.33 (C=O),
148.11 (CAr), 137.16 (CAr), 136.62 (CAr), 133.50 (CAr),
130.12 (2 × CHAr), 129.63 (CHAr), 128.60 (2 × CHAr),
127.15 (CHAr), 126.45 (CHAr), 122.84 (CHAr), 27.24
(CH), 23.03 (2 × CH3), 20.85 (CH3-Ar).
2. 3. Identification of Synthetized 
Compounds
2. 3. 1. GC-MS Analysis
MS spectra of samples of the synthesized com-
pounds were recorded on a 7890/7000B GC/MS/MS tri-
ple quadrupole system (Agilent Technologies, USA,
equipped with a Combi PAL auto sampler). The fused si-
lica capillary column HP-5MS (5% phenylmethylsiloxa-
ne, 30 m × 0.25 mm, film thickness 0.25 ìm, Agilent Tech-
nologies, Palo Alto, CA, USA) was used. The injector,
source and interface operated at 250, 230 and 300 °C, res-
pectively. The temperature program: from 60 for 5 min
isothermal to 300 °C at a heating rate of 8 °C/min and on
300 °C for 5 min isothermal. The solutions in hexane we-
re injected in split ratio 10:1. The carrier gas was helium
with a flow of 1.0 mL/min. Post run: back flash for 1.89
min, at 280 °C, with helium at 50 psi. MS conditions we-
re as follows: ionization voltage of 70 eV, acquisition
mass range 50–650, scan time 0.32 s. Semi-quantitative
analysis was carried out directly from peak areas in the
GC profile.
Linear retention indices (RI) were determined based
on the retention times of C8–C40 alkanes run on HP-5MS
column using the above mentioned temperature program-
me.41
2. 3. 2. NMR Analysis
1H NMR spectra were recorded in CDCl3 (isotopic
enrichment 99.95%) solutions at 25 °C using a Bruker
AVANCE 500 instrument (500.13 MHz for 1H, 125.76
MHz for 13C) using 5 mm inverse detection broadband
probes and deuterium lock.
2. 4. Antimicrobial Activity
2. 4. 1. Microbial Strains
The in vitro antimicrobial activity of the synthesized
compounds was tested against a panel of laboratory con-
trol strains belonging to the American Type Culture Col-
lection Maryland, USA. Gram-positive: Bacillus subtilis
ATCC 6633 and Staphylococcus aureus ATCC 6538;
Gram-negative: Escherichia coli ATCC 8739, Pseudomo-
nas aeruginosa ATCC 9027; fungal organisms: Aspergil-
lus niger ATCC 16404 and Candida albicans ATCC
10231. The Gram-negative bacteria Salmonella abony
NCTC 6017 and Salmonela typhimurium ATCC 14028
were obtained from the National Collection of Type Cul-
tures. All microorganisms were maintained at –20 °C un-
der appropriate conditions and regenerated twice before
use in the manipulations.
2. 4. 2. Screening of Antimicrobial Activity
The minimal inhibitory concentration (MIC) of es-
ters was determined based on a broth microdilution met-
hod in 96-well microtitre plates.42 The inocula of the bac-
terial strains were prepared from overnight broth cultures
and suspensions were adjusted to 0.5 McFarland standard
turbidity. Dimethyl sulphoxide (10% aqueous solution)
was used to dissolve and to dilute samples to the highest
concentration to be tested (stock concentrations 1 mg/m-
L). A serial doubling dilution of the samples was prepared
in a 96-well microtiter plate, using the method of Sarker et
al.43 with slight modifications. The minimal bacterici-
dal/fungicidal concentration (MBC/MFC) was evaluated
as the lowest concentration of tested samples at which
inoculated microorganisms were 99.9% killed. Tests were
carried out in triplicate.
2. 5. In silico Physico-chemical, Pharmacoki-
netic and Toxicological Properties of the
Synthetized Compounds
In order to obtain a complete picture of the synthesi-
zed compounds 3a–t an in silico study was performed.
Physico-chemical, pharmacokinetic and toxicological
properties of compounds were calculated using the Mo-
linspiration,44 admetSAR,45 DataWarrior46 and Toxtree
prediction tools.47
3. Results and Discussion
3. 1. Chemical Synthesis
A small focused library of twenty thymyl esters was
synthesized. To the best of our knowledge ten of twenty
compounds are new (i.e. 3i, 3k–s; Scheme 1).
Although enzyme-catalyzed esterification of alco-
hols of different structures is a well-established ap-
proach,48 the enzymatic esterification of phenols is not
frequently reported.49 Since a biocatalytic approach ap-
peared especially appealing to us, we have tried to repeat
the experimental protocol reported for the esterifcation of
functionalized phenols with Candida antarctica lipase
(CAL-B)49 using thymol and propanoic acid as substrates
and tert-butyl methyl ether and hexane as solvents. Howe-
ver, although no reaction occurred in our hands, the bioca-
talytic approach deserves further investigation within the
recent trends of green chemistry methodologies.
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Table 1. Thymyl esters: chemical entity, yields (%) and entry
R Yield Product Name and Number
(%)
CH3 85.00 Thymyl Acetate 3a
CH2Cl 85.00 Thymyl 2-Chloroacetate 3b
CH2CH3 82.00 Thymyl Propanoate 3c
CH2CH2CH3 84.00 Thymyl Butanoate 3d
CH(CH3)2 75.00 Thymyl 2-Methylpropanoate 3e
CH2(CH2)2CH3 87.00 Thymyl Pentanoate 3f
CH2CH(CH3)2 81.00 Thymyl 3-Methylbutanoate 3g
CH2(CH2)3CH3 79.00 Thymyl Hexanoate 3h
CH2(CH2)4CH3 84.00 Thymyl Heptanoate 3i
CH2(CH2)5CH3 85.00 Thymyl Octanoate 3j
CH2(CH2)6CH3 79.80 Thymyl Nonanoate 3k
CH2(CH2)7CH3 75.50 Thymyl Decanoate 3l
CH2(CH2)8CH3 82.00 Thymyl Undecanoate 3m
CH2(CH2)9CH3 76.30 Thymyl Dodecanoate 3n
CH2(CH2)10CH3 85.10 Thymyl Tridecanoate 3o
CH2(CH2)11CH3 72.05 Thymyl Tetradecanoate 3p
CH2(CH2)12CH3 68.90 Thymyl Pentadecanoate 3q
CH2(CH2)13CH3 95.06 Thymyl Hexadecanoate 3r
CH2(CH2)14CH3 72.50 Thymyl Heptadecanoate 3s
Ph 95.00 Thymyl Benzoate 3t
3. 2. Antimicrobial Activity
The results obtained in broth microdilution assay are
presented in Supplementary data, Table S1. The assayed
samples were less effective than antibiotic/antimycotic
used as reference standard and if noted, activity was never
greater than the values obtained for the parent compound
1 (MIC/MBC/MFC never exceeded 0.5 mg/mL, Supple-
mentary data, Table S1). The results are indicating selecti-
ve susceptibility of the microorganisms, with S. aureus
(3a,b,e), P. aeruginosa (3b,j,k,p) and C. albicans
(3a–e,g,n,p) being the most sensitive strains to synthesi-
zed derivatives. On the other hand, five microorganisms
(B. subtilis, E. coli, S. abony, S. typhimurium and A. niger)
were completely resistant to synthesized compounds te-
sted (initial concentration 1 mg/mL).
Five of our samples (3a,c,e,g,t) are matching the
samples tested by Mathela and collaborators,4 who were
making evaluation of antibacterial activity on Streptococ-
cus mutans (MTCC 890), S. aureus (MTCC 96), B. subti-
lis (MTCC 121), Staphylococcus epidermidis (MTCC
435) and E. coli (MTCC 723), and who reported the en-
hancement of the activity for esters in comparison to thy-
mol. For all other synthesized compounds antimicrobial
results are reported for the first time. An interesting fact is
that MIC values by Mathela4 were three- (2-methylpropa-
noate 3c and 3-methylbutanoate 3e) to even ten- (acetate
3a) times lower for B. subtilis than for thymol. Having in
best case comparable, but never greater MIC values than
for thymol itself, in our in vitro experiment we could not
confirm such results.4 The importance of free hydroxyl
group in the phenolic structure was confirmed in terms of
Scheme 2. Synthesis of thymyl esters: (a) chemical synthesis approach; (b) enzyme-catalyzed approach.
a)
b)
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activity when carvacrol was compared to its methyl et-
her,50 however results presented by Mathela4 are contrary
to the above-mentioned fact and to our results (Supple-
mentary data, Table S1).
3. 3. In silico Study
3. 3. 1. Physico-chemical Properties of the
Thymyl Esters 3a–t
Lipinski’s rule of 5 gives evaluation to drug-likeness
and determines if a substance with certain pharmacologi-
cal or biological activity has properties that would make it
a likely orally active drug in humans.51 Calculations of
important molecular parametars stated by Lipinski such as
fragment based contributions and correction factors
(miLog P), topological polar surface area (TPSA) and
drug-likeness were obtained by Molinspiration software.44
Drug-likeness score of compounds 3a–t is given in Suple-
mentary data, Table S2.
Seven compounds (3a–g) had miLogP values below
5 and thus were predicted to have sufficient oral bioavaila-
bility. The rest of the compounds were estimated as lypop-
hilic. All of the tested compounds (3a–t) had TPSA below
60 Å2, and thus were predicted to have both good intesti-
nal absorption and good BBB penetration. All of the te-
sted compounds (3a–t) had less than 10 H-bond acceptors
(nON) and less than 5 H-bond donors (nOHNH). The confor-
mational flexibility, described by the number of rotatable
bonds (nrotb), for 12 compounds (3a–k,t) was between 0
and 10, which warrants good oral bioavailability. Finally,
all compounds (3a–t) had both molecular weight (MW)
and molecular volume below 500.
Calculated physico-chemical properties showed that
seven thymyl esters (3a–g) were predicted to have good
oral bioavailability, with values for fragment based contri-
butions and correction factors miLogP < 5, TPSA < 140,
MW < 500, nON < 10, nOHNH < 5 and nrotb < 10.
3. 3. 2. Pharmacokinetic Properties of the
Thymyl Esters 3a–t
Absorption properties of compounds 3a–t were pre-
dicted by admetSAR45 (Supplementary data, Table S3).
The results suggested that all of the tested compounds
(3a–t) might be able to pass through blood-brain barrier
(BBB) and penetrate into the CNS, might be capable of
being absorbed by intestine, and were supposed to have
positive Caco-2 permeability. Moreover, compounds 3a–t
were predicted as non-substrates for P-glycoprotein, non-
inhibitors of P-glycoprotein, and as non-inhibitors against
renal organic cation transporter (ROCT).
Metabolic properties of the thymyl esters 3a–t were
predicted by admetSAR45 (Supplementary data, Table
S4). None of the compounds was predicted as CYP450
2C9 and 2D6 substrate, while 16 compounds (3b,d,f,h–t)
were predicted as CYP450 3A4 substrates. All of the te-
sted compounds were predicted as CYP450 1A2 inhibi-
tors, but none of them was predicted as CYP450 2D6 and
3A4 inhibitors. Moreover, 15 compounds (3b,d,h–t)
might be able to inhibit CYP450 2C19 enzyme, while on-
ly compound 3t was predicted as CYP450 2C9 inhibitor.
Almost all thymyl esters (3a–s) were predicted to have
low CYP inhibitory promiscuity, except compound 3t.
3. 3. 3. Toxicological Properties of the Thymyl
Esters 3a–t
The structural alerts for DNA and protein binding
for compounds 3a–t were predicted using Toxtree predic-
tion tool based on decision tree approach.47 Compounds
3a–t showed structural alerts for DNA binding as they
were predicted as compounds able to undergo Michael ad-
dition. Moreover, compounds 3a–t showed structural
alerts for protein binding due to their predicted ability to
undergo Michael addition, ability to participate in acyl
transfer and ability to undergo SN2 reactions (results given
in Supplementary data, Table S5).
Toxicological properties of compounds 3a–t predic-
ted by admetSAR45 have characterized compounds 3a–t
as weak HERG (human Ether-à-go-go-Related Gene) in-
hibitors, non-AMES toxic and non-carcinogens, but high-
ly toxic for fish, Tetrahymena pyriformis and honey bee.
Ready biodegradable were supposed to be six compounds
(3a,c–g). Depending on the risk for acute oral toxicity, on-
ly compound 3b was predicted as Category II, or com-
pound with LD50 value greater than 50 mg/kg but less than
500 mg/kg, while the rest of the tested compounds
(3a,c–t) were predicted as Category III, or compounds
with LD50 values greater than 500 mg/kg but less than
5000 mg/kg. According to the TD50 values, compounds
3a–t were predicted as »non-required« or non-carcinoge-
nic chemicals (Supplementary data, Table S6).
Only one study involving thymyl esters was under-
taken to establish the potential acute toxicity in animal
models.29 The esters shown no acute toxicity to mice at
doses higher than 5000 mg/kg which represents good con-
gruence and indicate the usefulness of data obtained in
our in silico study.
Toxicological properties of thymyl esters 3a–t pre-
dicted by DataWarrior46 have shown that only compound
3b has a high risk for all mutagenic, tumorigenic, repro-
ductive and irritant effects. Compound 3h was predicted
to have high risk for tumorigenic and irritant effects. Ho-
wever, all compounds were predicted to have high risk for
irritant effects (Supplementary data, Table S7).
4. Conclusion
We synthesized twenty esters of thymol, of which
ten represent new compounds. All of the compounds were
employed in antimicrobial bioassay and was found that
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lower representatives of the synthesized homologous se-
ries of esters are antimicrobials comparable to thymol and
can be considered as activity key holders, too. Results of
our in silico study predicted that seven esters (lower repre-
sentatives and short-chain fatty acids esters 3a–g) obey
Lipinski’s rule of five, showing drug-likeness. The rest of
the compounds were estimated as lipophilic. All com-
pounds, except thymyl 2-chloroacetate (3b) and thymyl
hexanoate (3h), were predicted as non-mutagenic, non-tu-
morigenic, non-AMES toxic and non-carcinogenic, but
highly toxic for fish, T. pyriformis and honey bee. They
are likely to be absorbed by intestine and were predicted
as ready biodegradable, weak HERG inhibitors, Category
III of risk for acute toxicity, with no risk for reproductive
effects, but with high risk for irritant effects. Taking in
consideration predicted in silico properties and estimated
drug likeness score, pharmacological and toxicological
profile, thymyl esters might be used as prodrugs. Among
the chemical bonds used to link parental drug and carrier,
esters have already proven to be promising due to their
amenability to hydrolysis in vivo and are most frequently
used in order to enhance the lipophilicity52 and passive
membrane transport.
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Z derivatizacijo izhodnih struktur terpenoidov lahko pogosto pripravimo nove spojine, ki imajo izbolj{ane biolo{ke ak-
tivnosti. Naravni fenolov derivat timol, ki biosintezno nastane po terpenski poti, predstavlja dobro znan biocid z
mo~nim antimikrobnim delovanjem in razli~nimi drugimi terapevtskimi aktivnostmi. Namen na{e {tudije je bil pripra-
viti majhno, fokusirano knji`nico dvajsetih timilnih estrov s pomo~jo ene same modifikacije fenolne funkcionalne sku-
pine v timolu. Deset izmed pripravljenih spojin je novih. Vsem sintetiziranim spojinam smo in vitro dolo~ili antimikrob-
ne lastnosti. Drug pomemben aspekt na{e {tudije pa je bila uporaba in silico ra~unskih metod za dolo~itev fizikalno-ke-
mijskih, farmakokineti~nih in toksikolo{kih lastnosti spojin, kar je omogo~ilo dodaten vpogled v njihove aktivnosti in
daje nove usmeritve za nadaljnje raziskave.
